For research use only. Not for therapeutic Use.
Voxilaprevir（Cat No.:I010171）is a potent NS3/4A protease inhibitor used in the treatment of chronic hepatitis C virus (HCV) infection. It blocks the NS3/4A protease, an essential enzyme for HCV replication and viral protein processing. Voxilaprevir is highly effective against multiple HCV genotypes and retains activity against protease inhibitor-resistant strains. It is typically used as part of combination therapies, enhancing sustained virologic response rates. With its favorable pharmacokinetics and robust efficacy, voxilaprevir represents a critical advancement in direct-acting antiviral therapies for managing and potentially curing HCV.
| Catalog Number | I010171 |
| CAS Number | 1535212-07-7 |
| Synonyms | GS9857 |
| Molecular Formula | C40H52F4N6O9S |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Storage | Store at -20°C |
| IUPAC Name | (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide |
| InChI | InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 |
| InChIKey | MZBLZLWXUBZHSL-FZNJKFJKSA-N |
| SMILES | CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C |
